Amundi Third-Party Distribution Investor Workshop: a powerful growth engine
Amundi Third-Party Distribution Investor Workshop: a powerful growth engine Today, Amundi, the leading European Asset Manager1 with €2.25tn2 of assets under management, will hold a workshop for investors focused on its Third-Party distribution platform.
Bombardier Begins Landmark Deliveries of Three Challenger 3500 Aircraft to Aloula Aviation
Delivery marks the first Challenger 3500 aircraft registered in Saudi Arabia, highlighting the global success of this renowned aircraft The best-selling Challenger 3500 business jet is ideally suited for customers in Saudi Arabia with its remarkable performance capabilities, superior runway ...
Palantir's Head Of Defense Says 'Xi Jinping Is Decoupling From Us' - Warns America Risks Losing Leverage If China Tech Shift Goes Unchecked - Palantir Technologies ( NASDAQ:PLTR )
Mike Gallagher, Head of Defense at Palantir Technologies Inc. PLTR, warned that Chinese President Xi Jinping is actively decoupling from the United States and that America risks losing negotiating leverage by ignoring this strategic shift. What Happened: "Xi Jinping is decoupling from us.
Transaction in Own Shares
London, 19 June 2025 - Endeavour Mining plc ( LSE:EDV, TSX:EDV ) ( "the Company" ) announces it has purchased the following number of its ordinary shares of USD 0.01 each from Stifel Nicolaus Europe Limited.
Bitcoin Scandal Fails to Topple Czech Government in No-Confidence Vote
A $45 million Bitcoin donation from a convicted darknet operator set off a political crisis and brought the Czech government to its knees.
Termination of Offer Discussions with Consortium
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.
Transgene Completes Initial Patient Screening in Phase II Part of TG4050 Trial in Operable Head and Neck Cancer
Phase I part showed 100% Disease-Free Survival ( DFS ) after a minimum of 2-year follow-up - providing clinical proof of principle for ...
